Technical Analysis for HGEN - Humanigen, Inc.

Grade Last Price % Change Price Change
F 0.00 -84.62% 0.00
HGEN closed down 84.62 percent on Thursday, January 4, 2024, on 7.39 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Mar 28
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Down Down Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
Volume Surge Other 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Crossed Above 20 DMA Bullish -84.62%
Volume Surge Other -84.62%
Calm After Storm Range Contraction -84.62%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Humanigen, Inc. Description

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The company's immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Clinical Medicine Immune System Immunotherapy Infectious Diseases Treatment Of Cancer Lymphoma Gene Therapy Infection Coronavirus Dysfunction Transplantation Chimeric Antigen Receptor T Cell Cytokine Hematopoietic Stem Cell Platform Technologies Host Disease Gilead Sciences Graft Versus Host Disease Eosinophil Coronavirus Infection Cytokine Release Syndrome Solid Cancers

Is HGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.239
52 Week Low 0.0001
Average Volume 279,236
200-Day Moving Average 0.07
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 0.00
Average True Range 0.00
RSI (14) 47.09
ADX 51.15
+DI 40.14
-DI 16.90
Chandelier Exit (Long, 3 ATRs) 0.00
Chandelier Exit (Short, 3 ATRs) 0.00
Upper Bollinger Bands 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.14
BandWidth 220.00
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram 0.0001
Fundamentals Value
Market Cap 23.82 Thousand
Num Shares 119 Million
EPS -0.51
Price-to-Earnings (P/E) Ratio 0.00
Price-to-Sales 0.01
Price-to-Book 9.20
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.00
Resistance 3 (R3) 0.00 0.00 0.00
Resistance 2 (R2) 0.00 0.00 0.00 0.00
Resistance 1 (R1) 0.00 0.00 0.00 0.00 0.00
Pivot Point 0.00 0.00 0.00 0.00 0.00
Support 1 (S1) 0.00 0.00 0.00 0.00 0.00
Support 2 (S2) 0.00 0.00 0.00 0.00
Support 3 (S3) 0.00 0.00 0.00
Support 4 (S4) 0.00